ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 225

Evaluating Fibromyalgia Symptoms in Transgender Patients

Dana Levit1, Jacob Ablin 1, Valerie Aloush 1 and Iris Yaish 1, 1Tel Aviv Sourasky medical center, Tel Aviv, Israel

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibromyalgia, sex hormones and pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Fibromyalgia & Other Clinical Pain Syndromes Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia Syndrome (FMS), characterized by widespread pain and fatigue, is known to be more prevalent in women, and has frequently been associated with stress is various models. In the current study we have evaluated the prevalence of fibromyalgia symptoms among Transgender men and women, in attempt to correlate such symptoms with gender dysphoria and gender transformation due to hormonal therapy.

Methods: Participants were recruited among patients followed at a specialized transgender clinic at the endocrinology institute of a large tertiary medical center. Participants were at various stages of the process of gender reassignment, including hormonal treatment.

After providing informed consent, participants were asked to answer the Widespread Pain Index (WPI) and the Symptom Severity Scale (SSS), in order to document the presence of symptoms related to the fibromyalgia spectrum and in order to determine the prevalence of fibromyalgia, according to the 2010-2011 diagnostic criteria.

Results: Thirty-six transgender men [Female-to-male (FTM)] and 29 transgender women [Male-to-female (MTF)] answered the questionnaires. Eight individuals form the FTM group met fibromyalgia criteria (22.2%). Only 1 individual from the MTF group met the criteria for fibromyalgia (3.4%). Among FTM individuals, 13 were evaluated both before and after initiating androgen-based hormonal treatment, in order to evaluate the effect of such treatment on symptoms.

Out of 4 individuals fulfilling fibromyalgia criteria before receiving hormonal therapy, 3 remained unchanged when re-evaluated on treatment, while 1 reported alleviation of symptoms. One individual developed fibromyalgia symptoms after 1 year of hormone treatment. 

Conclusion: In this preliminary study, Fibromyalgia symptoms were found to be highly prevalent among Transgender men (FTM), at a rate significantly higher than reported in the general population. Fibromyalgia symptoms appeared to be less frequent among Transgender women (MTF).

These results are relevant for professionals treating transgender individuals in the medical or psychological field.  Further research into the effects of gender and of hormone treatment on fibromyalgia and chronic pain are indicated.


Disclosure: D. Levit, None; J. Ablin, None; V. Aloush, None; I. Yaish, None.

To cite this abstract in AMA style:

Levit D, Ablin J, Aloush V, Yaish I. Evaluating Fibromyalgia Symptoms in Transgender Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/evaluating-fibromyalgia-symptoms-in-transgender-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluating-fibromyalgia-symptoms-in-transgender-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology